Literature DB >> 2158554

Dissociation of mu opioid tolerance from receptor down-regulation in rat spinal cord.

K Nishino1, Y F Su, C S Wong, W D Watkins, K J Chang.   

Abstract

The effect of continuous intrathecal infusions of opioids was studied in rats. Chronic intrathecal infusion of the highly selective mu agonist, [NMPhe3, D-Pro4]morphiceptin produced a rapid onset of tolerance to the drug in the analgesic test. However, membrane prepared from the spinal cords of the rats chronically infused with a low dose of the drug showed no statistically significant change in the number of mu or delta receptor binding sites. In addition, membrane prepared from rats challenged with a single high-dose bolus injection of [NMPhe3, D-Pro4]morphiceptin did not produce alterations in the receptor binding number. If the chronically treated rats were challenged with an acute bolus dose of [NMPhe3, D-Pro4]morphiceptin, there was a significant decrease in the number of binding sites. The reduced binding site number was observed for the mu ligand but not for the delta ligand. A similar decrease of receptor binding can also be achieved by chronic infusion of the drug at high doses. Scatchard plot showed a decrease of maximum mu binding sites in the membranes prepared from the combined chronic infusion-acute injection treated rats. Brain tissue from the same rats showed no change in the number of mu and delta receptor binding sites, indicating that the down-regulation of mu receptors was confined to the spinal cord only. Morphine did not induce receptor down-regulation by acute, chronic or combined treatments. These results suggest that in the rat spinal cord, tolerance can be induced without apparent receptor down-regulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158554

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  A novel knock-in mouse reveals mechanistically distinct forms of morphine tolerance.

Authors:  Johan Enquist; Joseph A Kim; Selena Bartlett; Madeline Ferwerda; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-05-11       Impact factor: 4.030

2.  Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G.

Authors:  Y-J Wang; P Huang; A Ung; J A Blendy; L-Y Liu-Chen
Journal:  Neuroscience       Date:  2012-01-03       Impact factor: 3.590

3.  Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy mu-opioids.

Authors:  H Ammer; R Schulz
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

4.  Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unit.

Authors:  J D Tobias; J K Deshpande; D F Gregory
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

5.  Let-7 microRNAs and Opioid Tolerance.

Authors:  Ying He; Zaijie Jim Wang
Journal:  Front Genet       Date:  2012-06-21       Impact factor: 4.599

Review 6.  Chaperone-like effects of cell-permeant ligands on opioid receptors.

Authors:  Yong Chen; Lee-Yuan Liu-Chen
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.